High MAP in Septic Shock With Hypertension
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01443494|
Recruitment Status : Completed
First Posted : September 29, 2011
Results First Posted : June 16, 2014
Last Update Posted : July 6, 2017
|Condition or disease||Intervention/treatment||Phase|
|Septic Shock||Other: NE||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||19 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||High Mean Arterial Pressure Target Improves Microcirculation in Septic Shock Patients With Previous Hypertension|
|Study Start Date :||June 2011|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||June 2012|
Experimental: NE group
Adjust NE dose to titrate MAP to usual level regardless of fluid responsiveness when after EGDT.
- Mean Arterial Pressure [ Time Frame: Target MAP stabilization for 30 min ]
As chronic hypertensive patients were supposed to have undergone more blood pressure measurements in daily life than non-hypertensive ones, the averaged MAP acquired from patients' physical examination records of the last two years was registered and assumed as patients' usual level of MAP and target MAP. If patients' medical records were incomplete, a detailed enquiry about the target MAP to their next kin was performed.
After stabilization for 30 min, basal measurements including hemodynamic and microcirculatory measurements were taken, 20 min apart, the NE doses were increased to titrate MAP to the target level. Patients were allowed to stabilize for 30 min before taking new measurements.
- Perfused Vessel Density [ Time Frame: Target MAP stabilization for 30 min ]Increasing MAP from 65 mm Hg to target level. The sublingual microcirculation was measured by sidestream dark field, including the parameters of perfused vessel density
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01443494
|Zhongda Hospital Southeast University|
|Nanjing, Jiangsu, China, 210000|
|Study Director:||Haibo Qiu, MD,PhD||Southeast University|